NCT05803382 2026-03-18
Testing the Addition of an Anti-Cancer Drug, ZEN003694, to the Usual Chemotherapy Treatment (Capecitabine) for Metastatic or Unresectable Cancers
National Cancer Institute (NCI)
Phase 1 Recruiting
Clinical Trials
12 trialsNCT07477743 2026-03-17
A Phase Ib Clinical Study on the Safety and Efficacy of HC010 Combinations in Advanced Solid Tumors
HC Biopharma Inc.
Phase 1 Recruiting
NCT04808323 2026-03-16
MRI-Guided Adaptive Radiation Therapy for Organ Preservation in Rectal Cancer
Medical College of Wisconsin
Phase 1 Recruiting
NCT07024615 2026-03-13
A Study of ASP2138 Given Before Surgery, Then Chemotherapy After Surgery, in People With Pancreatic Ductal Cancer
Astellas Pharma Inc
Phase 1 Recruiting
NCT05412082 2026-02-06
SMART TNT
University of Miami
Phase 1 Recruiting
NCT06065371 2025-12-19
Sacituzumab Govitecan in Combination With Capecitabine for Advanced Gastrointestinal Cancers After Progression on Standard Therapy
Henry Ford Health System
Phase 1 Recruiting
NCT04703101 2025-11-10
Short Course Radiation Therapy and Combination Chemotherapy for the Treatment of Stage II-III Rectal Cancer
Jonsson Comprehensive Cancer Center
Phase 1 Recruiting
NCT04615013 2025-10-30
NBTXR3, Chemotherapy, and Radiation Therapy for the Treatment of Esophageal Cancer
M.D. Anderson Cancer Center
Phase 1 Recruiting
NCT06839105 2025-05-31
A Clinical Study to Evaluate the Safety and Tolerability of AWT020 in Patients With Advanced Malignancies
Shanghai Junshi Bioscience Co., Ltd.
Phase 1 Recruiting
NCT06825624 2025-02-13
ARTEMIS-102: HS-20093 Combinations in Patients with Advanced Metastatic Colorectal Cancer
Hansoh BioMedical R&D Company
Phase 1 Recruiting
NCT05700084 2024-04-19
Tolerability and Bioavailability of Utidelone Capsule in Patients With Advanced Solid Tumors
Beijing Biostar Pharmaceuticals Co., Ltd.
Phase 1 Recruiting
NCT05912075 2024-02-08
PRAAR1
Gustave Roussy, Cancer Campus, Grand Paris
Phase 1 Recruiting